Skip to main content
NCBI home page
Thorax logoLink to Thorax
. 1995 Jul;50(7):750–754. doi: 10.1136/thx.50.7.750

Efficacy of inhaled salmeterol in the management of smokers with chronic obstructive pulmonary disease: a single centre randomised, double blind, placebo controlled, crossover study.

C S Ulrik 1
PMCID: PMC474647  PMID: 7570409

Abstract

BACKGROUND--The acute response to bronchodilators in patients with chronic obstructive pulmonary disease (COPD) is modest; it has, however, been suggested that these patients may benefit from long term treatment. METHODS--To investigate the efficacy of salmeterol in smokers with moderate to severe COPD a double blind, randomised, crossover comparison was performed between salmeterol (50 micrograms twice daily) and placebo in 63 patients with stable COPD (mean age 65 years). Prior to inclusion, all patients had a forced expiratory volume in one second (FEV1) of < 60% of predicted and an improvement in FEV1 of < 15% following 400 micrograms inhaled salbutamol. Patients received four weeks of therapy with each of the treatment regimens. Assessment of efficacy was made with recording of morning and evening peak expiratory flow rates (PEF), respiratory symptoms, and use of rescue salbutamol. FEV1 was measured before and after nebulised salbutamol prior to randomisation and at the end of each treatment period. RESULTS--Morning PEF values were higher during the salmeterol than during the placebo period, although the mean treatment difference was small (12 l/min (95% confidence limits 6 to 17)). No difference in mean evening PEF values was found. Diurnal variation in PEF, assessed as the difference between the morning PEF and that of the previous evening, was more pronounced during the placebo than during the salmeterol period. The mean spirometric values (including reversibility in FEV1) obtained at the end of the two treatment periods were similar. Compared with placebo, treatment with salmeterol was associated with lower daytime and night time symptom scores and less use of rescue salbutamol both during the day and the night. The patients rated the treatment with salmeterol better than treatment with placebo. CONCLUSIONS--This study shows that, compared with placebo, treatment with salmeterol produces an improvement in respiratory symptoms and morning PEF values in patients with moderate to severe COPD. Treatment with long acting beta agonists may therefore result in an improvement in functional status, even in patients suffering from apparently nonreversible obstructive pulmonary disease.

Full text

PDF
750

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Anthonisen N. R., Wright E. C. Response to inhaled bronchodilators in COPD. Chest. 1987 May;91(5 Suppl):36S–39S. [PubMed] [Google Scholar]
  2. Barnes P. J., Pride N. B. Dose-response curves to inhaled beta-adrenoceptor agonists in normal and asthmatic subjects. Br J Clin Pharmacol. 1983 Jun;15(6):677–682. doi: 10.1111/j.1365-2125.1983.tb01549.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Corris P. A., Neville E., Nariman S., Gibson G. J. Dose-response study of inhaled salbutamol powder in chronic airflow obstruction. Thorax. 1983 Apr;38(4):292–296. doi: 10.1136/thx.38.4.292. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Evald T., Keittelmann S., Sindrup J. H., Lange P. The effect of inhaled terbutaline on FEV1, FVC, dyspnoea and walking distance in patients with chronic obstructive lung disease. Respir Med. 1992 Mar;86(2):93–96. doi: 10.1016/s0954-6111(06)80221-0. [DOI] [PubMed] [Google Scholar]
  5. Gottfried S. B., Redline S., Altose M. D. Respiratory sensation in chronic obstructive pulmonary disease. Am Rev Respir Dis. 1985 Nov;132(5):954–959. doi: 10.1164/arrd.1985.132.5.954. [DOI] [PubMed] [Google Scholar]
  6. Guyatt G. H., Townsend M., Pugsley S. O., Keller J. L., Short H. D., Taylor D. W., Newhouse M. T. Bronchodilators in chronic air-flow limitation. Effects on airway function, exercise capacity, and quality of life. Am Rev Respir Dis. 1987 May;135(5):1069–1074. doi: 10.1164/arrd.1987.135.5.1069. [DOI] [PubMed] [Google Scholar]
  7. Lundback B., Rawlinson D. W., Palmer J. B. Twelve month comparison of salmeterol and salbutamol as dry powder formulations in asthmatic patients. European Study Group. Thorax. 1993 Feb;48(2):148–153. doi: 10.1136/thx.48.2.148. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Mahler D. A., Rosiello R. A., Harver A., Lentine T., McGovern J. F., Daubenspeck J. A. Comparison of clinical dyspnea ratings and psychophysical measurements of respiratory sensation in obstructive airway disease. Am Rev Respir Dis. 1987 Jun;135(6):1229–1233. doi: 10.1164/arrd.1987.135.6.1229. [DOI] [PubMed] [Google Scholar]
  9. Palmer J. B., Stuart A. M., Shepherd G. L., Viskum K. Inhaled salmeterol in the treatment of patients with moderate to severe reversible obstructive airways disease--a 3-month comparison of the efficacy and safety of twice-daily salmeterol (100 micrograms) with salmeterol (50 micrograms). Respir Med. 1992 Sep;86(5):409–417. doi: 10.1016/s0954-6111(06)80008-9. [DOI] [PubMed] [Google Scholar]
  10. Pineda H., Haas F., Axen K., Haas A. Accuracy of pulmonary function tests in predicting exercise tolerance in chronic obstructive pulmonary disease. Chest. 1984 Oct;86(4):564–567. doi: 10.1378/chest.86.4.564. [DOI] [PubMed] [Google Scholar]
  11. Ramsdell J. W., Nachtwey F. J., Moser K. M. Bronchial hyperreactivity in chronic obstructive bronchitis. Am Rev Respir Dis. 1982 Nov;126(5):829–832. doi: 10.1164/arrd.1982.126.5.829. [DOI] [PubMed] [Google Scholar]
  12. Tandon M. K., Kailis S. G. Bronchodilator treatment for partially reversible chronic obstructive airways disease. Thorax. 1991 Apr;46(4):248–251. doi: 10.1136/thx.46.4.248. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Taylor D. R., Buick B., Kinney C., Lowry R. C., McDevitt D. G. The efficacy of orally administered theophylline, inhaled salbutamol, and a combination of the two as chronic therapy in the management of chronic bronchitis with reversible air-flow obstruction. Am Rev Respir Dis. 1985 May;131(5):747–751. doi: 10.1164/arrd.1985.131.5.747. [DOI] [PubMed] [Google Scholar]
  14. Teale C., Morrison J. F., Jones P. C., Muers M. F. Reversibility tests in chronic obstructive airways disease: their predictive value with reference to benefit from domiciliary nebuliser therapy. Respir Med. 1991 Jul;85(4):281–284. doi: 10.1016/s0954-6111(06)80097-1. [DOI] [PubMed] [Google Scholar]
  15. Ullman A., Svedmyr N. Salmeterol, a new long acting inhaled beta 2 adrenoceptor agonist: comparison with salbutamol in adult asthmatic patients. Thorax. 1988 Sep;43(9):674–678. doi: 10.1136/thx.43.9.674. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Thorax are provided here courtesy of BMJ Publishing Group

RESOURCES